Carbocyclic Thromboxane A2(CTA2) is a stable analog of TXA2 which acts as a potent coronary vasoconstrictor at low concentrations. Unlike other vascular TP receptor agonists, CTA2 is a potent inhibitor of prostanoid-induced platelet aggregation, specifically arachidonic acid-induced aggregation (IC50 = 4-5 µM). CTA2 also exhibits dose-dependent and selective inhibition of TXB2 synthesis in rabbit platelets at concentrations between 1 and 100 µM.
1. Lefer, A M., et al., 1980. Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2. Proceedings of the National Academy of Sciences of the United States of America. 77(3): 1706-10. PMID: 6929517
See how others have used Carbocyclic Thromboxane A2 (CAS 74034-56-3). Click on the entry to view the PubMed entry .
PMID: # 15015658 Matsuo, M. et al. 2004. J. Neurooncol. 66: 285-292.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.